Aerosolised salbutamol in two doses as a treatment for preterm infants with developing bronchopulmonary dysplasia.
Phase 4
Recruiting
- Conditions
- Chronic Lung Disease (CLD) and Bronchopulmonary Dysplasia (BPD)10028971
- Registration Number
- NL-OMON33377
- Lead Sponsor
- Isala Klinieken
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Preterm infants suspect for developing BPD (> 35 wk PMA) who receive ventilatory support and/or oxygen therapy > 21% and clinically suspected of developing BPD.
Exclusion Criteria
Neonates with major congenital malformations, neonates with a life expectancy of less than 72 hours, neonates who receive potassium supplementation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Main study endpoint is the fall in serum potassium. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary parameters are heart rate, level of oxygen supplementation,<br /><br>respirator settings/height of the CPAP-flow, behaviour and dyspnea of the child<br /><br>during inhalation, saturation and events of apnea.</p><br>